"Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.
Glaucoma is a leading cause of blindness. But because vision damage often occurs gradually, mos"...
RESTASIS® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
DOSAGE AND ADMINISTRATION
Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using. Instill one drop of RESTASIS® ophthalmic emulsion twice a day in each eye approximately 12 hours apart. RESTASIS® can be used concomitantly with artificial tears, allowing a 15 minute interval between products. Discard vial immediately after use.
Dosage Forms And Strengths
Ophthalmic emulsion containing cyclosporine 0.5 mg/mL
Storage And Handling
RESTASIS® ophthalmic emulsion is packaged in sterile, preservative-free single-use vials. Each vial contains 0.4 mL fill in a 0.9 mL LDPE vial; 30 or 60 vials are packaged in a polypropylene tray with an aluminum peelable lid. The entire contents of each tray (30 vials or 60 vials) must be dispensed intact.
30 Vials 0.4 mL each - NDC 0023-9163-30
60 Vials 0.4 mL each - NDC 0023-9163-60
Store at 15-25°C (59-77°F).
Allergan, Inc. Irvine, CA 92612, U.S.A. Revised: 2013This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/14/2013
Additional Restasis Information
Restasis - User Reviews
Restasis User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.